Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma

Authors :: Matthew T. Seymour
D. Ford
Marcia Hall
L.C. Thompson
Russell D. Petty
Fareeda Y. Coxon
Gary Middleton
L. Stevenson
S. P. Stenning
David Cunningham
Justin Waters
Alicia Okines
William H. Allum
L. Evans
T. Iveson
Sarah Slater
David J. Smith
Ruth E Langley
Chris Plummer
S Falk
Source :: Journal of Clinical Oncology. 29:4092-4092
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 4092 Background: Perioperative chemotherapy is a standard treatment for localised gastric/OGJ adenocarcinoma. B is a monoclonal antibody targeting vascular endothelial growth factor A. Addition of ...

Full Text Access

Tools